Paragraph IV Disputes Master Symposium

Master the Necessary Skills to Rise to the Newfound Challenges of the Pharmaceutical Patent Endgame

ACI’s industry-leading Paragraph IV Disputes Master Symposium enters its fifth iteration this fall. This event will pick up where ACI Paragraph IV conference left off to bring you up-to-the minute information on the latest developments affecting ANDA litigation.   Preeminent patent litigators representing brand name and generic drug makers, leading in-house counsel, and esteemed jurists will provide insights on such matters as:  

The impact of TC Heartland on jurisdiction and venue The legal and business repercussions of Helsinn Amgen v. Sandoz from an ANDA litigator’s point of view The FDA Final MMA Rule Novartis v. Noven and differing standards of review Secondary considerations in obviousness reviews

Alternative forums: PTAB and ITC Oil States vs. Greene’s Energy Group and the constitutionality of IPR proceedings Exceptional case findings Reverse payment settlements Patent lawsuit risk assessment and other IP due diligence essentials

  To learn more, download the agenda now.  

Judicial Insights from: United States District Court

 

Patent Trial and Appeal Board, USPTO

 

In-house Insights from:

 

AbbVie Akorn Pharmaceuticals Amneal Pharmaceuticals Astellas Pharma US, Inc. Eagle Pharmaceuticals, Inc. Eli Lilly and Company

Fresenius Kabi USA, LLC Gilead Sciences, Inc. Impax Laboratories Otsuka Sarepta Therapeutics

Don’t sit back while your competition gains valuable knowledge from this conference. Register to secure your space now! REGISTER NOW   Event Contacts